Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration

NCT05197270 is registered in ClinicalTrials.gov with 4D Molecular Therapeutics as lead sponsor.

NCT NCT05197270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05197270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration
Lead sponsor
4D Molecular Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 9, 2021
Completion date
January 31, 2031
Enrollment
215 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular (wet) age-related macular degeneration